ReviewNutrients2020
Beta-Cell Mass in Obesity and Type 2 Diabetes, and Its Relation to Pancreas Fat: A Mini-Review.
Review in Nutrients, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 106 citations in OpenAlex.
- Trial
- Article
- Is high insulin protective or detrimental? Mathematical modeling reveals the base of the iceberg.American journal of physiology. Endocrinology and metabolism · 2026Article
- Mechanisms and Production of Hypoglycaemic Peptides: Exploring the Potential ofFood science & nutrition · 2026Review
- Characterization of individuals in whom body weight loss precedes diabetes onset: a retrospective, observational, longitudinal cohort study based on health checkup in Japan.Endocrine journal · 2026Observational
- Liensinine alleviates type 2 diabetes mellitus through modulating the pancreatic β cell function and gut microbiota.Genes & nutrition · 2025Article
- From NAFPD to MAFPD: a literature review of implications of a nomenclature change.Hepatobiliary surgery and nutrition · 2025Review
- Dual-layer microneedles for immunomodulation and infection-responsive therapy in diabetic foot ulcers.Materials today. Bio · 2025Article
- Emerging Roles of Post-Translational Modifications in Metabolic Homeostasis and Type 2 Diabetes.International journal of molecular sciences · 2025Review
- Both subcutaneous semaglutide and calorie restriction improves pancreatic cell hyperplasia and gut microbiota in high-fat diet-induced obese mice.Nutrition & metabolism · 2025Article
- Dynamic Rendition of Adipose Genes Under Epigenetic Regulation: Revealing New Mechanisms of Obesity Occurrence.Current issues in molecular biology · 2025Review
- The Impact of PET Imaging on Translational Medicine: Insights from Large-Animal Disease Models.Biomolecules · 2025Review
- Analysis glycemic variability in pregnant women with various type of hyperglycemia.BMC pregnancy and childbirth · 2025Article
- Evolving Characteristics of Type 2 Diabetes Mellitus in East Asia.Endocrinology and metabolism (Seoul, Korea) · 2025Review
- The Importance of Edible Medicinal Mushrooms and Their Potential Use as Therapeutic Agents Against Insulin Resistance.International journal of molecular sciences · 2025Review
- Correlation Between the Controlled Attenuation Parameter and the Prevalence of T2DM in Southern China: A Retrospective Cross-Sectional Study.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Article
- Fabrication and Preclinical Evaluation of Hyaluronic Acid/Aminoclay Nanocomposite Microneedles for Noninvasive Delivery of Semaglutide in Anti-Obesity Therapy.International journal of nanomedicine · 2025Article
- Henagliflozin Increases Serum and Salivary Levels of High-Molecular-Weight Adiponectin in Patients with Type 2 Diabetes in the Community.International journal of general medicine · 2025Article
- Therapeutic potential of magnesium sulfate in improving duodenal homeobox 1 and PPARG coactivator 1 alpha genes to reduce pancreatic insulin resistance in F1 offspring of diabetic rats.Iranian journal of basic medical sciences · 2025Article
- Ranolazine: An Established Anti-anginal Drug with Emerging Antidiabetic Potential Supported by Preclinical and Clinical Evidence.Cardiovascular & hematological disorders drug targets · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Type 2 diabetes (T2DM) is characterized by insulin resistance and beta-cell dysfunction. Although insulin resistance is assumed to be a main pathophysiological feature of the development of T2DM, recent studies have revealed that a deficit of functional beta-cell mass is an essential factor for the pathophysiology of T2DM. Pancreatic fat contents increase with obesity and are suggested to cause beta-cell dysfunction. Since the beta-cell dysfunction induced by obesity or progressive decline with disease duration results in a worsening glycemic control, and treatment failure, preserving beta-cell mass is an important treatment strategy for T2DM. In this mini-review, we summarize the current knowledge on beta-cell mass, beta-cell function, and pancreas fat in obesity and T2DM, and we discuss treatment strategies for T2DM in relation to beta-cell preservation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.